Loading organizations...
Peptone is a biotechnology company developing novel small-molecule therapeutics designed to selectively target intrinsically disordered proteins (IDPs). The company employs a proprietary computational biophysics platform, integrating artificial intelligence with experimental physics, to identify and validate drug candidates for challenging protein targets. This innovative approach allows for the systematic exploration of the IDP landscape, addressing a significant frontier in drug discovery by focusing on proteins previously considered undruggable.
The company was founded by Kamil Tamiola, a protein physicist who also serves as its Chief Executive Officer. Dr. Tamiola’s foundational insight stemmed from the critical, yet often overlooked, role of intrinsically disordered proteins in various biological processes and diseases. Recognizing the immense therapeutic potential locked within these dynamic structures, he established Peptone to leverage advanced computational methods to unlock new possibilities for precision medicine.
Peptone aims to enable the development of new treatments for diseases where IDPs play a key role, collaborating with pharmaceutical partners to bring these novel therapies to patients. The company's long-term vision centers on transforming the therapeutic landscape by systematically addressing historically intractable targets, thereby advancing human health through a deeper understanding and modulation of protein dynamics.
Peptone has raised $42.0M across 2 funding rounds.
Peptone has raised $42.0M in total across 2 funding rounds.
Peptone has raised $42.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2022 | $40M Series A | Bessemer Venture Partners, F Prime Capital | Allos Ventures, Firstminute Capital, Hoxton Ventures, Innovation Works, Walden Catalyst Ventures, Alex Oppenheimer, Michael Stoppelman, Novartis DRX | Announced |
| Jan 1, 2021 | $2M Seed | Hoxton Ventures | Evolution VC Partners, Firstminute Capital, Flucas Ventures, Shawn Modarresi, Motley Fool Ventures, Alex Oppenheimer, JAY Z, Kevin Hart, Michael Stoppelman, Seth Goldman, Brent Hoberman, DRX Capital, Henry FOX | Announced |
Peptone is a biotechnology company developing novel small-molecule therapeutics that target intrinsically disordered proteins (IDPs), a class of proteins linked to diseases like cancer and inflammation that traditional tools like AlphaFold 3 cannot model.[3][6] Founded in 2018 in the UK, it serves pharmaceutical researchers and patients by addressing "undruggable" proteins through an integrated platform combining experimental biophysics, supercomputing, machine learning, bespoke mass spectrometry, and protein disorder lab expertise, solving the problem of modeling and drugging disordered protein structures that disrupt function in diseases.[1][2][3][6] The company raised $40 million in April 2022, established its primary R&D hub in Bellinzona, Switzerland, in spring 2022—now the world's largest lab of its kind—and plans to expand to 30 specialized employees there.[1][2]
Peptone was founded in 2018 in the United Kingdom by Dr. Kamil Tamiola, who serves as CEO, emerging from expertise in experimental biophysics to tackle IDPs, which are challenging due to their lack of stable structure.[1][2][3] Tamiola's vision integrated supercomputing and machine learning with physics-based approaches, gaining early traction through a $40 million funding round in April 2022 led by investors like Bessemer Venture Partners and Hussein Kanji.[1][2][4] A pivotal moment came in spring 2022 when Peptone relocated its R&D operations to Bellinzona, Switzerland, in the Greater Zurich Area, supported by local authorities; this site now hosts advanced labs across two floors, with plans for up to 20 new jobs by end-2023.[2]
Peptone rides the AI-driven drug discovery wave, targeting the "undruggable" 80-90% of the proteome comprising IDPs, which are implicated in cancers and inflammatory conditions but historically evaded due to structural disorder.[3][6] Timing aligns with advances in computational biophysics and machine learning post-AlphaFold, enabling Peptone to unlock new therapeutic pockets amid a biotech funding resurgence and demand for precision medicines.[1][4] Market forces like rising oncology needs and Switzerland's biotech ecosystem (e.g., Greater Zurich incentives) favor expansion; Peptone influences the field by pioneering IDP drugging, potentially reshaping pipelines for pharma giants seeking novel modalities.[2][3]
Peptone is poised to advance IDP therapeutics into clinical stages, leveraging its Swiss hub for pipeline expansion in oncology and inflammation, with team growth to 30+ specialists driving compound validation.[1][2] Trends like multimodal AI-physics integration and global biotech hubs will accelerate progress, potentially yielding first-in-class drugs as IDP targeting matures. Its influence may grow through partnerships, amplifying impact on "invisible" disease drivers and redefining biotech's proteome frontier—echoing its mission to drug the disordered.
Peptone has raised $42.0M in total across 2 funding rounds.
Peptone's investors include Bessemer Venture Partners, F-Prime Capital, Allos Ventures, Firstminute Capital, Hoxton Ventures, Innovation Works, Walden Catalyst Ventures, Alex Oppenheimer, Michael Stoppelman, Novartis dRx, Evolution VC Partners, Flucas Ventures.
